Eledon Pharmaceuticals Inc (ELDN) — Cash Flow-to-Debt Ratio
Eledon Pharmaceuticals Inc (ELDN) has a Cash Flow-to-Debt Ratio of -0.14x as of December 2025, meaning its operating cash flow of $-14.09 Million could theoretically repay 0% of its total liabilities ($100.82 Million) in one year. Check Eledon Pharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eledon Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Eledon Pharmaceuticals Inc across 14 annual periods. Also explore Eledon Pharmaceuticals Inc total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Eledon Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Eledon Pharmaceuticals Inc. For market capitalisation and broader financial context, see Eledon Pharmaceuticals Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.62x | $-62.34 Million | $100.82 Million | ▲ +22.5% |
| 2024 | -0.80x | $-47.27 Million | $59.27 Million | ▲ +14.3% |
| 2023 | -0.93x | $-39.53 Million | $42.48 Million | ▲ +71.8% |
| 2022 | -3.30x | $-28.42 Million | $8.61 Million | ▲ +25.2% |
| 2021 | -4.41x | $-28.91 Million | $6.55 Million | ▼ -91.1% |
| 2020 | -2.31x | $-15.21 Million | $6.59 Million | ▲ +75.6% |
| 2019 | -9.45x | $-13.86 Million | $1.47 Million | ▼ -101.4% |
| 2018 | -4.69x | $-11.89 Million | $2.53 Million | ▲ +54.8% |
| 2017 | -10.38x | $-14.94 Million | $1.44 Million | ▲ +17.5% |
| 2016 | -12.58x | $-36.52 Million | $2.90 Million | ▼ -90.7% |
| 2015 | -6.60x | $-41.24 Million | $6.25 Million | ▼ -32.5% |
| 2014 | -4.98x | $-21.12 Million | $4.24 Million | ▼ -2716.2% |
| 2013 | -0.18x | $-15.48 Million | $87.55 Million | ▲ +1.8% |
| 2012 | -0.18x | $-9.33 Million | $51.86 Million | — |